Anika Therapeutics Inc.
ANIK | NASDAQ
$20.93
+$0.23 (+1.11%)
Sep 22, 2026, 12:32 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 112.82M | 119.91M | 120.79M | 113.83M | 147.79M | 130.46M |
Cost of Revenue | 49.01M | 43.91M | 38.26M | 40.61M | 64.85M | 61.43M |
Gross Profit | 63.81M | 76M | 82.53M | 73.22M | 82.94M | 69.03M |
Operating Income | -11.05M | -5.1M | 844K | 3.67M | 2.62M | -28.32M |
Interest Income | n/a | n/a | 2.31M | 654K | n/a | 498K |
Pretax Income | -9.31M | -2.76M | 3.16M | 4.32M | 2.43M | -28.62M |
Net Income | -10.88M | -56.39M | -82.67M | -14.86M | 4.13M | -23.98M |
Selling & General & Admin | 49.09M | 55.56M | 59.93M | 51.23M | 74.1M | 60.06M |
Research & Development | 25.77M | 25.54M | 21.76M | 18.32M | 27.33M | 23.43M |
Other Expenses | n/a | n/a | n/a | n/a | -21.1M | 13.85M |
Operating Expenses | 74.86M | 81.1M | 81.69M | 69.55M | 80.33M | 97.35M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | 800K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 123.87M | 125.01M | 119.95M | 110.16M | 145.18M | 158.78M |
Income Tax Expense | 672K | 6.06M | 6.6M | 2.12M | -1.71M | -4.64M |
Shares Outstanding (Basic) | 14.34M | 14.72M | 14.66M | 14.56M | 14.4M | 14.22M |
Shares Outstanding (Diluted) | 14.34M | 14.72M | 14.66M | 14.56M | 14.63M | 14.22M |
EPS (Basic) | -0.76 | -3.83 | -5.64 | -1.02 | 0.29 | -1.69 |
EPS (Diluted) | -0.76 | -3.83 | -5.64 | -1.02 | 0.28 | -1.69 |
EBITDA | -3.58M | 5.36M | 17.37M | 18.81M | -4.16M | -1M |
EBIT | -9.31M | -2.76M | 3.16M | 4.32M | -18.48M | -14.47M |
Depreciation & Amortization | 5.73M | 8.12M | 14.22M | 14.49M | 14.32M | 13.46M |
Add to Watchlist
Select watchlists to add or remove ANIK